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The development of new vasculature plays a significant role in a number of chronic disease 
states, including neoplasm growth, peripheral arterial disease, and coronary artery disease, 
among many others. Traumatic injury and hemorrhage, however, is an immediate, often dramatic 
pathophysiologic insult which can also necessitate neovascularization to promote healing. 
Traditional understanding of angiogenesis involved resident endothelial cells branching outward 
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from localized niches in the periphery. Additionally, there are a small number of circulating 
endothelial progenitor cells which participate directly in the process of neovessel formation. The 
bone marrow stores a relatively small number of so-called pro-angiogenic hematopoietic 
progenitor cells (PACs) – that is, progenitor cells of a hematopoietic potential that differentiate 
into key structural cells and stimulate or otherwise support local cell growth/differentiation at the 
site of angiogenesis. Following injury, a number of cytokines and intercellular processes are 
activated or modulated to promote development of new vasculature. These processes initiate and 
maintain a robust response to vascular insult, allowing new vessels to canalize and anastomose 
and provide timely oxygen delivering to healing tissue.  Ultimately as we better understand the 
key players in the process of angiogenesis we can look to develop novel techniques to promote 
healing following injury.  
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Introduction 
The development of new vasculature plays a significant role in traumatic injury and hemorrhage 
particularly during the acute phase of organ repair. Long-held theories concerning the 
development of new vasculature primarily focus on local endothelial and circulating endothelial 
progenitor cells. A cell of hematopoietic lineage stored in bone marrow, termed the 
proangiogenic hematopoietic progenitor cell (PAC), has also been identified that plays an 
important role in paracrine signaling and structural development of new vessels.(1, 2) This 
otherwise quiescent cell type interacts with a multitude of key signaling molecules both for 
storage and release as needed and is a key contributor to the development of needed vasculature 
in the post-natal human. The cascade of cytokine release and PAC mobilization is complex, 
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multifaceted, and tightly regulated by a number of important feedback loops. This cascade is 
particularly important in an abrupt deviation from homeostasis, as in the case of traumatic injury, 
particularly considering the immediately increased need for oxygen and nutrients by injured 
tissues.(3) Study of these HSCs may ultimately provide a better understanding of the varying 
healing potential of injured and severely ill patients. The purpose of this review is to: 1) 
summarize the process of angiogenesis at the level of neovessel formation, 2) identify key 
signaling molecules involved in the angiogenic process, and 3) identify how proangiogenic stem 
cells can improve outcomes following traumatic injury.  
Angiogenesis 
Embryology 
The human vascular system begins to develop around the seventeenth day of gestation. Clusters 
of primarily early erythrocytes are surrounded by vascular endothelial growth factor-positive 
endothelial progenitor cells (EPCs) in the yolk sac.  These EPCs will develop into endothelial 
cells, and ultimately coalesce to form tubes in a process termed vasculogenesis. As the 
responsibility for blood cell formation is transitioned from the yolk sac to the embryonic organs, 
these same organs become colonized with mature hematopoietic stem cells. Until the time of 
birth, the primary responsibility for the development and differentiation of hematopoietic cells 
lies with the liver before ultimately colonizing the bone marrow(4). As the embryo develops, the 
splanchnic mesoderm differentiates into a primitive vascular system. Further budding of the 
vascular branches – termed angiogenesis – subsequently occurs (5). Vasculogenesis in the 
developing embryo is subject to a number of regulatory pathways and molecules, including 
mechanical strain(6), fibroblast growth factors and associated tyrosine kinase receptors(7), as 
well as specific cell adhesion molecules such as VE-cadherin and Ang-2(8).   
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Conditions Precipitating Angiogenesis and the Vascular Extracellular Matrix 
Angiogenesis is the result of a complex cascade of signaling molecules and cell-cell interactions. 
In a physiologic state, normal human endothelial cells are closely connected via vascular 
endothelial cadherin (VE-cadherin) at adherens junctions, and occludin and JAM-1 at tight 
junctions. These junctions form a transendothelial barrier against the free passage of ions, 
solutes, and lipids from the apical to basolateral cell surfaces.(9) They also provide the basis for 
imperative cell-cell functions which allow the endothelial cell, under the appropriate conditions, 
to quickly sprout new cells in a direction of need.(10, 11) Transgenic mice with knockout of 
genes encoding involved proteins – for example-catenin(12) – demonstrated impaired 
endothelial maturation, vessel fragility, and disorganization that was frequently incompatible 
with life.   
The pathophysiologic conditions under which angiogenesis occurs vary – i.e. wound healing, 
cancer, hypoxia, etc. – but the cellular mechanisms underlying the eventual sprouting of new 
vessel structures have commonalities. Microvascular permeability to plasma proteins appears to 
be a relatively early event in the formation of new vessels. As have been described, both inter-
endothelial and trans-endothelial passages are opened as a downstream effect of vascular 
endothelial growth factor (VEGF) signaling. This allows the translocation of proteins necessary 
for the scaffolding of the fibrin-rich extracellular matrix.(13) As endothelial cells begin to 
migrate into the surrounding extracellular matrix (ECM), a number of key molecules exert strong 
effects on proliferation and tubulogenesis. Fibronectin, an ECM protein, is upregulated from its 
otherwise barely detectable concentration in angiogenetic pathologies.(14) Endothelial cells 
involved in neovascularization have demonstrated unfolding of fibronectin to create a 
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pericellular network of fibrils, which supports organization and migration of tubular cells in a 
type I collagen-dominant extracellular matrix.(15, 16) 
Another group of molecules key to maintaining perivascular homeostasis are laminins. Laminins 
are a group of polymers containing three polypeptide chains - , , and , giving rise to 16 
different isoforms, each with tissue-specific functions.(17) The 4 subunit, in particular, plays a 
critical role in interacting with integrins, namely v3 and 31, all of which serve to interact 
with endothelial cells and promote angiogenesis.(18) These molecules, present in the vascular 
basement membrane, have shown important roles in maintenance of vessel homeostasis as well, 
particularly in settings of homeostasis and fluid shear stress.(19) Laminin, type IV collagen, 
fibrin, and other factors make up the perivascular ECM which provides the initial scaffolding 
through which new vessels may form. 
The Process of Angiogenesis 
Angiogenic endothelial cells are generally characterized as either leading “tip” cells or trailing 
“stalk” cells. Tip cells, selected by Delta-like 4-Notch1 signaling and induced to angiogenic 
activity by VEGF-A, lead the way into the vascular basement membrane (vBM).(20) Notch 
signaling has been shown to not only identify tip cells, but keep stalk cells in position and 
prevent development of tip-like behavior. Maintaining cells in a stalk position is crucial for 
lumen formation and connection to existing vasculature as the new vessel sprouts and 
migrates.(21) 
In order to sprout new vasculature, angiogenic cells must first penetrate and degrade the vBM. 
Recent evidence using an in vivo model of transgenic and knockout mice demonstrated that 
endothelial cells, after sensing angiogenic signals, develop podosome rosettes, which are capable 
of invading and degrading the vBM.(22) This appears to be the key initial step in development of 
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new tubular vascular branches. Recent evidence shows that podosome formation coincides with 
loss of perivascular type IV collagen in a VEGF/Notch-dependent pathway.(23) 
Following entry into the basement membrane, proangiogenic endothelial cells are tasked with 
proliferation and new tubule formation, followed by maturation. Relatively little is known about 
the migration of endothelial cells in a three-dimensional matrix. Endothelial cells have been 
shown to migrate in functionally distinct patterns depending on the concentration of certain 
structural substrates in the surrounding migration matrix. In dense Matrigel, endothelial cells 
demonstrated an elongated pattern depositing dense ECM with migration, whereas in fibrillar 
collagen I-dominant matrix (notably lacking laminin), the cells take on a rounded shape of 
amoeboid-type migration with significant intracellular blebbing noted.(24) As cells migrate, 
endothelial cell interactions with ECM components promote tube formation. Laminin-511, 
particularly the 5 short arm, has demonstrated activity for both endothelial cell attachment and 
tube formation in vitro.(25) Hemodynamic stress within existing vessels, coupled with lumen 
formation in angiogenic sprouts prior to connection, result in a tightly regulated expansion of 
existing vasculature into new territory.(26, 27) 
As new vessels sprout, cell-cell signaling continues to play a crucial role, not only for 
maintenance of homeostasis but tight control of cells moving around one another and developing 
appropriate polarity. Appropriate apico-basal polarity is essential for tubule formation by 
migrating endothelial cells, a key part of a multistep process to allow branching endothelium to 
carry blood products.(28) During sprouting, VE-cadherin integrity at cell-cell junctions once 
more plays a crucial role. VE-cadherin is phosphorylated and translocated from the cell 
membrane in settings with high VEGF and/or Notch concentration.(29) This variability allows 
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cells to jostle position in areas of need while maintaining the structural integrity of the existing 
vascular structure.  
Angiogenesis in the Healing Process 
When tissue is injured, the initial angiogenetic response results in a surge of capillary growth that 
is orders of magnitude more dense than uninjured tissue. This occurs by the process described 
above and is mediated in accordance with the surge in cell signaling molecules that will be 
described in later sections. Capillaries sprout quickly and are subsequently pruned to create 
mature vasculature for the delivery of adequate oxygen and nutrients to the healing bed. This is 
correlated with a decline in circulating proangiogenic factors and allows secondary stages of 
healing to begin. Indeed, the argument can be made that the angiogenic response to injury results 
in wounds that heal with marked fibrosis. The resulting massive surge in capillary density may 
promote local inflammation to an unnecessarily robust degree.(30) 
Clinically, a great deal of attention has been paid to understanding and optimizing wound healing 
and angiogenesis. While the key steps remain consistent – that is, migration into and through 
extracellular matrix, tube formation, maturation, and anastomosis – conditions that cause a 
global alteration of physiology such as polytrauma, induce a cascade of cell signals which can 
induce or impair any or all of those steps of angiogenesis. We will subsequently discuss those 
signals, as well as their known or presumed role in the development of new vasculature.  
Cells Involved in Angiogenesis 
Endothelial outgrowth involves two general types of precursor cells which fall under the 
umbrella of endothelial progenitor cell (EPC). The first, termed the late-outgrowth endothelial 
colony forming cell, is a relatively differentiated, committed endothelial cell that is used to form 
new or repair damaged endothelium. These cells, in response to angiogenic signals, align in tip 
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or stalk roles as described above to facilitate the outward branching of existing vasculature. The 
second cell type, proangiogenic hematopoietic progenitor cells (PACs), serve to stimulate and 
enhance angiogenesis via paracrine mechanisms. These PACs are frequently bone marrow-
derived cells released into circulation via a variety of signaling cascades.(31) 
Flow cytometry has been utilized to elucidate the extracellular markers specific to PACs, and 
while the particular cell surface signature of these molecules has been known for some time, 
their function is continually being described. The most frequent cell surface protein signature 
used to identify circulating proangiogenic hematopoietic-lineage cells is 
CD34+CD133+VEGFR2+.(32, 33) Peichev, et al., demonstrated a distinct cell lineage of 
CD34+CD133+VEGFR2+ cells which formed a neo-intima on left ventricular assist devices, 
thereby uncovering a crucial role in angiogenesis.(34) Data has demonstrated that CD33+CD45+ 
cells are of hematopoietic-restricted lineage, and do not differentiate into endothelial cells proper 
to form new blood vessels.(35) Nevertheless, this signature of cell surface proteins does appear 
to identify a group of phenotypically distinct hematopoietic cells which participate in postnatal 
angiogenesis.  
Hematopoietic progenitor cells stored in bone marrow migrate into the periphery in the setting of 
traumatic hemorrhage. They have been shown to be a potential marker for mortality following a 
major traumatic event.(3) Proper identification of these cells - as well as the associated 
circulating stimuli for release - may not only yield prognostic information, but may also allow 
for cellular therapies to be developed for rapid revascularization following organ injury.(36) 
 
Maintenance of Quiescent PACs 
At steady state, there exists a delicate cellular signaling interplay that serves to maintain a supply 
of pro-angiogenic hematopoietic progenitors. The first of these cell surface molecules is C-X-C 
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chemokine motif ligand 12 (CXCL12). CXCL12 is a chemokine mutually exclusive to the seven 
transmembrane G-protein coupled receptor CXCR4, which is expressed on bone marrow-derived 
hematopoietic stem and progenitor cells. Bone marrow stromal cells express CXCL12 at steady 
state, which promotes maintenance of CD34+/CD38-/low HSCs in mice.(37, 38) This has been 
shown in mice to promote maintenance of bone marrow HPCs and HSCs.(37) When the 
CXCL12-CXCR4 axis is compromised, both maintenance and migration of HPCs are impaired. 
When the CXCL12-CXCR4 axis is impaired, PAC maintenance and migration are both 
impaired. AMD3100 is a specific inhibitor of CXCR4 that competes with CXCL12, multiple 
studies have demonstrated that administration of AMD3100 resulted in rapid mobilization of 
hematopoietic progenitor cells from bone marrow to peripheral circulation.(39) This includes 
early PACs with long-term repopulation potential. (40-42) Bach, et al., demonstrated that 
antagonism of CXCR4 with AMD3100 in pigs who sustained polytrauma resulted in a sharp 
increase in circulating CXCL12 levels, suggesting a regulatory feedback loop.(43) Indeed, a 
recent study has demonstrated the imperative role of the CXCR4-CXCL12 axis in HPC 
maintenance, as well as homing for repopulation of bone marrow after myeloablation.(44) With 
this understanding of the key player in HPC maintenance, we can look at contributors to 
migration, particularly in the setting of traumatic injury, that serve to mobilize this cohort of 
proangiogenic cells when required.  
 
Mobilization of HPCs from Bone Marrow Niche 
Perhaps more intricate than the cellular interplay required for HPC maintenance, a number of 
cytokines and chemokines function to mobilize these cells when called upon.(Figure 1) These 
cyto/chemokines frequently have multiple functions as it relates to the immediate healing 
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process. Each will be discussed both generally and as it relates specifically to the mobilization of 
HPCs from the bone marrow. Traumatic injury itself is not an entirely unique physiologic 
phenomenon. Many of the cellular responses to injury parallel those of other well-studied 
processes, including shock and sepsis.  
Following traumatic injury, plasma levels of circulating CXCL12 increase with even higher 
concentration adjacent to the site of injury in humans.(45)Elevation of CXCL12 after trauma is 
similarly observed in patients with severe sepsis/septic shock.(46) As stated above the CXCL12-
CXCR4 axis is crucial to interaction with bone marrow-derived HPCs. While it may serve to 
promote steady-state quiescence, it also serves as a key homing molecule when proangiogenic 
cellular precursors are needed in an extramedullary capacity – namely at the site of injury. Akin 
to interaction with HPCs, inhibition of the CXCL12-CXCR4 axis impaired migration of bone 
marrow-derived mesenchymal stem cells.(47) The ligand is able to cross the bone marrow 
endothelium and reach the endosteum, interacting with early PACs and hematopoietic stem cells 
(HSCs).(48) Jin, et al., demonstrated in a mouse model that platelet-originated CXCL12 
enhances neovascularization by its interaction with CXCR4+ cells of hematopoietic lineage.(49) 
(Figure 2) 
To fully understand the role of CXCL12, an attempt should be made to understand additional 
downstream factors that are affected when it is upregulated. One such factor is matrix 
metalloproteinase 9 (MMP-9). MMP-9 belongs to a family of zinc endopeptidases that function 
at a physiologic pH to degrade ECM. The proenzymes are cleaved via thiol-modifying reagents, 
heat, chaotropic agents, and various other proteases.(50) MMP-9 has been shown to result in 
elevated CXCL12 levels, and reciprocally CXCL12 increased MMP-9 concentration in bone 
marrow cells.(51) Increases in circulating MMP-9 concentration have been observed following 
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traumatic insult.(52-54) This is quite similar to studies demonstrating the increase of MMP-9 in 
patients with sepsis.(55-57) MMP-9 release has been shown to be associated with endotoxemia 
and hematopoietic cell migration from bone marrow to peripheral organs.(58)The broad 
degradative function of MMP-9 results in a number of downstream effects. With regards to 
blood vessel development, the importance of MMP-9 begins with embryonic vasculogenesis. 
Theodore, et al., demonstrated that MMP-9 inhibition in zebrafish resulted in decreased tail 
vascularity and increased numbers of PACs within caudal hematopoietic tissue.(59) Post-
embryologically, endothelial cells create and release several matrix metalloproteases, including 
MMP-1, MMP-2, MMP-9, and MT1-MMP. The shedding of membrane vesicle-associated 
components containing MMP-2, MMP-9, and MT1-MMP comes about as a rapid response to 
angiogenetic signals.(60) The ECM-degrading property of MMPs acts locally to break down 
perivascular ECM and well as distantly to mobilize HSCs and proangiogenic HPCs. MMP-9 has 
been shown in mice to affect migration of PACs from the quiescent to the proliferative niche via 
release of soluble Kit-ligand (sKitL). This allows PACs to rapidly respond to BM suppressive 
insult and repopulate myeloid and lymphoid progenitor cell lineages after significant 
mobilization into the periphery.(61) By distilling this expansive degradative function, we can 
deduce that MMP-9 is not only key for angiogenesis at the level of local vascular injury, but also 
for disruption of HPCs in a quiescent state, thus promoting mobilization into the periphery. 
A third key molecule involved in both maintenance and mobilization of PACs is transforming 
growth factor-beta (TGF). TGF is a pleiotropic polypeptide that has a role in processes from 
embryological development to wound healing. TGF also exerts powerful, variable effects on 
angiogenesis. Firstly, it plays an important role in the transformation of HSCs into endothelial 
cells.(62) The receptor with which local TGF is interacting appears to play an important role in 
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determining the function of this molecule. Activation of ALK5 generally favors stabilization in 
new vasculature, while activation of ALK1 favors sprouting.(63) In the course of inhibiting 
angiogenesis, TGF has demonstrated a dose-dependent inhibition of SMAD2, Notch pathway, 
and VEGFR2.(64) 
Besides direct effects on angiogenesis at the site of new vessel development, TGF also acts in 
the bone marrow to induce quiescence in hematopoietic stem and progenitor cells. Recent 
research has identified the interaction of TGF with activation of downstream plasminogen 
activator inhibitor (PAI)-1 as important in the maintenance of PACs residing within the bone 
marrow niche. With this axis inhibited, PACs demonstrated MT1-MMP-dependent motility 
patterns and egress from bone marrow.(65) 
Following traumatic injury, circulating levels of TGF have been shown to be elevated, peaking 
on post-injury day 3.(66) This is thought to contribute to the transient immunosuppression that 
occurs following trauma, but may also have an effect on responsive angiogenesis with the 
ALK5-dependent inhibition of PACs and angiogenic endothelial cells. Additionally, TGF 
exposure has been shown to induce formation of endothelial podosome rosettes both in vivo and 
in vitro, which allow invasion into perivascular basement membrane.(67, 68) The precise role of 
elevated TGF on the mobilization of PACs from bone marrow remains unclear, however the 
role of this cytokine at the site of neovascularization is well-described.  
Like TGF, vascular endothelial growth factor (VEGF) plays a role in both PAC mobilization 
and angiogenesis. Regarding the former, VEGF receptor 2-positive (VEGFR2+) endothelial cell 
forming unit concentration in peripheral blood increased in response to VEGF administration, 
suggesting the importance of VEGF in releasing proangiogenic progenitor cells from the bone 
marrow. This interaction appears to be MMP-9 dependent, as MMP-9-/- did not demonstrate the 
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same response to VEGF.(61)Similarly, depleted expression of VEGFR-2 via adeno-associated 
virus-mediated CRISPR-associated endonuclease has been demonstrated to inhibit angiogenesis 
in vitro.(69)VEGF levels following traumatic injury have been observed to be insignificantly 
altered; however, sVEGFR1 was positively correlated with injury severity score (ISS). 
Alternately, sVEGFR2 was negatively correlated with ISS. This finding is consistent with acute 
lung injury in sepsis, with multi-organ downregulation of VEGFR2 genes noted in experimental 
critical illness.(70)While not as overtly pro-angiogenic as VEGFR2, VEGFR1 is shown to be 
related to pathological angiogenesis (i.e., ischemia, tumorigenesis) as it is expressed on 
endothelial cells.(71, 72) 
Krüppel-like factor-10 (KLF-10) is a member of the zinc-finger family of proteins with diverse 
regulatory function, including that of osteoblasts, hepatocytes, and bone marrow-derived 
progenitor cells. KLF-10 targets the VEGFR-2 promotor in HSCs with pro-angiogenic behavior. 
Pro-angiogenic cells derived from the bone marrow demonstrated strong expression of 
transforming growth factor beta 1 (TGF-β1)-responsive KLF-10, according to Wara et al. 
Functionally, KLF-10 knockout resulted in impaired blood flow recovery in murine hind limb 
ischemia models.(73) Insofar as reconstitution of the endothelium, KLF-10 has been shown to be 
integral to the mobilization of pro-angiogenic precursor cells from the bone marrow, such that 
KLF-10-/- mice demonstrate significantly impaired re-endothelization of injured carotid arteries 
after BM transplantation. To further investigate this phenomenon, the authors of this study 
evaluated the presence of other essential chemokines in BM HSC maintenance and migration. 
KLF-10-/- mice had impaired expression of CXCR4, which is imperative to maintenance and 
homing of PACs as previously discussed.(74) 
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Other members of the Krüppel-like factor family, including KLF-2, KLF-4, KLF-5, KLF-6, and 
KLF-15 have demonstrated a role in angiogenesis through various other pathways. KLF-2, which 
is expressed on mature endothelial cells and upregulated in response to stress, has demonstrated 
ability to rejuvenate circulating proangiogenic cells, thereby promoting angiogenesis in times of 
need.(75) KLF-4 has been shown to activate VEGF signaling to stimulate angiogenesis.(76) 
KLF-15 acts via activation of the bone morphogenetic protein endothelial cell precursor-derived 
regulator (BMPER) pathway to stimulation new vessel growth.(77) KLF-5 appears to act by a 
variety of pathways, including VEGF, PAI-1, and PDGF, among a host of others.(78) 
Taken in sum, these factors – CXCL12, MMP-9, TGF, and VEGF – which frequently arise 
from the site of injury or directly adjacent circulating cells, work in concert to promote 
angiogenesis and mobilize distantly-stored key PACs to aid in this healing process.  
The Nervous System and PAC Maintenance and Migration 
In addition to egress of PACs from bone marrow stimulated by circulating cyto/chemokines, the 
autonomic nervous system has been shown to play a key role in maintaining and releasing PACs 
and stem cells from bone marrow niches. This is critical, as the sympathetic nervous system is 
acutely upregulated in response to traumatic injury and neuroimmune modulation is crucial to 
response and recovery.(79)In addition to chemokine-related steady state maintenance of PACs 
within the bone marrow niche, PACs have been shown to express neurotransmitter receptors in 
various quantities. Kalinkovich, et al., showed that more primitive CD34+CD38(-/low) cells 
express higher levels of neurotransmitter receptors, namely dopamine and β-adrenergic 
receptors. This is in concert with the high degree of sympathetic innervation of the bone marrow, 
which stores a large amount of dopamine.(80) When sympathetic tone is altered or dopamine 
conversion to norepinephrine is inhibited, egress of PACs from bone marrow when treated with 
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granulocyte-colony stimulating factor (G-CSF) has been shown to be markedly impaired.(81) 
Macrophages also have the ability to modulate catecholamine release in the bone marrow, thus 
mobilizing PACs.(82) Méndez-Ferrer, et al., demonstrated that circadian norepinephrine release 
by the sympathetic nervous system controlled CXCL12 expression, which fluctuated in counter 
to concentration of PACs in peripheral blood.(83)  The importance of β-adrenergic signaling in 
CD34+ cell maintenance and migration has been studied, as engraftment of progenitor cells, 
motility, and proliferation are all increased with greater neurotransmitter exposure.(84) 
Nerve growth factor (NGF) is a polypeptide first identified in the 1950s, noteworthy in this 
context for its ability to induce growth and differentiation in the developing embryo neural 
system. A review published in 1987 by Levi-Montalcini identifies this as a key function, and it 
has been further studied in nerves and non-nerve cells alike.(85, 86) With regards to 
angiogenesis, Cantarella, et al., demonstrated interaction with trkA and p57 proteins present on 
human umbilical vein endothelial cells. NGF was found to promote angiogenesis and endothelial 
cell proliferation in vivo.(87) Notably, NGF has been shown to be produced by microvascular 
endothelial cells in the human dermis, with potential implications for healing following traumatic 
injury.(88) Additionally, NGF has been shown to stimulate aorta endothelial cell migration via 
PI3K-dependent and ERK-dependent pathways, migrating according to an NGF gradient.(89) 
NGF and VEGF have been shown to have similar effects on the cardiovascular and nervous 
systems, respectively, and research is ongoing into the synergy between these two 
molecules.(90) 
Altered Systemic Physiology Resulting in PAC Mobilization 
In addition to the cellular response to and release of the cytokines and chemokines in the 
previous section, local and systemic physiologic changes following injury and shock result in 
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mobilization of distant PACs. The first of these is hypoxia. Hypoxia itself results in the release of 
bone marrow-derived PACs into circulation.(91) In addition to this direct effect, hypoxia induces 
the formation and stability of hypoxia inducible factor 1 (HIF-1). The ⍺ subunit of HIF-1 is 
constitutively produced and rapidly degraded in normoxic conditions. In the setting of hypoxia, 
this degradation is halted and tissue and plasma concentrations are increased, and HIF-1⍺ 
subsequently heterodimerizes with the HIF-1β subunit.(92)HIF-1 is closely linked with 
angiogenesis, and numerous studies have demonstrated its importance in angiogenesis in disease 
states including cancer, lung injury, and traumatic brain injury.(93)HIF-1, when bound to 
hypoxia response elements, induces transcription of VEGF, angiopoietin 1 (ANGPT1) and 
ANGPT2, placental growth factor, platelet derived growth factor B, and in total greater than 2% 
of genes encoded by endothelial cells.(94)This results clinically in a compensatory response of 
the vasculature.(95) This has been shown in the setting of sepsis, wherein HIF-1 upregulation 
was essential to endothelial repair in inflammatory lung injury.(96)Insofar as it is related to bone 
marrow-derived HSCs and CXCL12, the increased concentration of HIF-1 may lead to 
upregulation of CXCL12 and increased interaction with CXCR4+ PACs. The ⍺ subunit of an 
alternate isoform of HIF - HIF-2⍺ - has been shown to enable bone marrow derived cells to 
overcome CXCL-12/CXCR4 retention signals, thus increasing migration from marrow into 
circulation, as in the migration of plasma cells in multiple myeloma.(97) 
In addition to upregulation of HIF, hypoxia upregulates erythropoietin, a hypoxia-regulated 
glycoprotein which has been extensively studied for both its endocrine effects on erythropoiesis 
and autocrine/paracrine effects in hypoxia. EPO exerts a chemotactic effect on endothelial cells 
and functions as a proangiogenic factor much like VEGF or FGF, a phenomenon that has been 
well-described since at least 1990.(98-100) Moreover, EPO interacts with human mesenchymal 
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stem cells to augment angiogenesis, as well as activation of MMP-2.(101)In addition to 
erythropoiesis, Heeschen and colleagues demonstrated that EPO increased the number of 
circulating endothelial progenitor cells and hematopoietic stem cells capable of participation in 
angiogenesis. Santhanam, et al. demonstrated that this process is critically dependent on 
endothelial nitric oxide synthase (eNOS).(102, 103) Endothelial progenitor cells in the presence 
of EPO show increased survival and efficacy in the setting of pulmonary vascular repair, and 
ultimately demonstrated improved pulmonary vessel angiogenesis.(104) Furthermore, EPO 
administration following dermal injury resulted in increased microvessel density at the site of 
injury.(105) EPO is a potent stimulator of erythroid and hematopoietic progenitors from the bone 
marrow niche, including cells identified as proangiogenic hematopoietic progenitor cells, and has 
been shown to be elevated following traumatic injury. Overall, administration of EPO has 
demonstrated improvement in survival following traumatic injury.(106) Conferring survival 
benefit, particularly at the vessel and microvessel level, is a phenomenon that is also seen in 




Rather than considering angiogenesis as occurring within a small, tightly regulated portion of 
existing endothelium, research has demonstrated that a small number of circulating and bone 
marrow-derived cells of hematopoietic lineage facilitate and augment angiogenesis. These cells 
respond to similar signaling cascades, home to areas of need, and play a crucial role in both 
signaling and new vessel development. The role that PACs play in the physiologic response to 
system dysfunction – as in the setting of traumatic injury – is an active area of research. 
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Augmenting the activity of these cells has the potential to improve vascularization of healing 
wounds, transiently ischemic tissues, and injured solid organs. Our goal is to identify 
pharmacologic or mechanistic means of improving host response to injury and blood vessel 
formation at areas of greatest need. Much in the way pro-hematopoietic cytokine administration 
(i.e. EPO) has improved survival in trauma patients, we hope to utilize an understanding of the 
factors in PAC mobilization to identify alternative methods to improve trauma patient survival.  
Future Directions 
As our understanding of the imperative role of endothelial progenitor cells and pro-angiogenic 
hematopoietic stem cells increases, applications including vascularizing mechanistically 
constructed tissues allow a peek into possible roles for further evaluation of vascular 
structures.(108) Identification of PACs allows new technologies to emerge which dramatically 
enhance how we understand wound healing and oxygen/nutrient delivery.  We may then begin to 
develop targeted therapies for patients in which angiogenesis is key to post-traumatic healing and 
overall survival.  
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Figure Legends 
Figure 1. Representative flowchart depicting the numerous cellular processes that ultimately 
result in the release of PACs from bone marrow and the eventual sprouting of neovasculature at 
the site of injury.  
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Figure 2. Schematic representation of post-traumatic angiogenesis. A) site of injury; B) Native 
vasculature at injury site. Circulating platelets contribute to angiogenesis via the release of 
CXCL12, while adjacent cells at the level of injury release MMP-9, TGFβ, and VEGF to aid in 
vascular development and recruit additional cells; C) At the level of neovascularization, the 
budding vessel forms a podosome rosette, led into the vascular basement membrane via 
endothelial “tip” cells, with “stalk” cells providing progressive support; D) At the level of the 
endothelial cell, occludins, Jam-1, and VE-Cadherin support the intercellular barrier, adjacent to 
a vascular basement membrane (vBM) composed of pericam, nidogen, and laminin, supported 
by a Type IV collagen scaffold; E) Erythropoietin is released from the kidney in response to the 
heterodimerization of HIF-2.   
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Table 1. Review of key signaling molecules in angiogenesis and mobilization of proangiogenic 
HSCs. 
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